Peptide of the Week: GLOW and KLOW — 10% Off This Week
Peptide of the Week: GLOW and KLOW — 10% Off This Week
PT-141 (Bremelanotide) is a synthetic peptide derived from the melanocortin system, particularly targeting MC1R and MC4R receptors.
It has become one of the most studied peptides in behavioral, neurological, and melanocortin research models.
Unlike many pathways that act indirectly, PT-141 interacts directly with neural melanocortin receptors — making it valuable for labs studying:
PT-141 is not a PDE-5 analogue and operates through a completely different research mechanism.
Research models suggest PT-141 may influence:
A key melanocortin receptor involved in:
Associated with:
PT-141 is of high interest in neuroscience labs because it interacts centrally, not peripherally.
This sets it apart from many other peptides and makes it valuable for research into:
PT-141 appears in preclinical literature focused on:
All discussion remains strictly academic and preclinical.
| Property | Details |
|---|---|
| Peptide name | PT-141 (Bremelanotide) |
| Class | Melanocortin receptor peptide |
| CAS | 189691-06-3 |
| Sequence | Ac-Nle-c[Asp-His-DNal(2’)-Arg-Trp-Lys]-OH |
| Research targets | MC1R, MC4R |
Researchers often choose PT-141 because:
Its distinct mechanism makes it a unique candidate for receptor-level investigation.
| Feature | PT-141 | Kisspeptin |
|---|---|---|
| Primary receptors | MC1R / MC4R | GPR54 |
| Research category | Melanocortin | Hypothalamic |
| CNS involvement | Strong | Moderate |
| Pathway type | Direct receptor agonist | GnRH-linked modulation |
PT-141 is uniquely melanocortin-focused, making it valuable in neurological receptor research.
Yes — for research use only.
It is not for human use or medical applications.
No.
PT-141 works through melanocortin receptors, not nitric-oxide or vascular pathways.
Most traditional treatments for erectile dysfunction are PDE5 inhibitors that act on the vascular system to increase blood flow. PT-141 is fundamentally different; it is a non-hormonal peptide that targets the Melanocortin receptors (MC3R and MC4R) in the hypothalamus. By activating these central pathways, it triggers sexual desire and arousal directly in the brain, making it effective for individuals who do not respond to blood-flow-based medications.
Yes. While PT-141 (Bremelanotide) is FDA-approved for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD), it is extensively researched for its off-label potential in men. In female models, it is studied for its ability to restore the “internal spark” of desire. In male models, it is investigated for its dual-action of increasing libido while also facilitating nitric oxide-mediated erections.
In 2026, researchers are increasingly looking at “Synergistic Stacks.” PT-141 is often compared to its parent peptide, Melanotan II, which also has pro-erectile effects but carries significant tanning properties. Researchers also investigate the co-administration of PT-141 with low-dose PDE5 inhibitors, observing a significantly enhanced erectile response compared to either agent alone.
PT-141 is a robust cyclic heptapeptide, but like all peptides, it is sensitive to environmental stressors. Lyophilized powder should be stored at -20°C for long-term preservation. Once reconstituted with bacteriostatic water, the solution is stable for 4–8 weeks when kept refrigerated at 2-8°C. To maintain experimental integrity, avoid repeated freeze-thaw cycles and protect the vial from direct UV light.
Reproducible CNS research requires absolute purity to avoid “metabolic noise” or paradoxical side effects like severe nausea. Luxara Labs ensures every batch of PT-141 undergoes 3rd-party HPLC and MS testing to verify 99% purity. We provide expedited, temperature-stable shipping across Canada and the USA to ensure that whether you are studying libido in Ontario or neuro-signaling in California, your materials arrive with their molecular integrity fully intact.
Join our list and get an instant 10% discount code — valid for first-time buyers.
